

HEAD AND NECK DISEASE SITE COMMITTEE

CHELSEA HOTEL, TORONTO, ON

ROOM: WREN A&B

SUNDAY MAY 5TH, 2024, 10:00 AM – 1:00 PM

CO-CHAIRS : JOHN HILTON AND SCOTT BRATMAN
SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

- *To interpret and address, through clinical trial and translational research, the disease burden associated with head and neck malignancies in Canada.*
- *To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.*
- *To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group or its collaborators.*
- *To identify mentoring opportunities for new investigators.*

10:00 am Welcome

10:05 am Proposals

Chemo-pembrolizumab & eftilagimod aLpha In CPS<20% recurrent/metAstatic caNCER of the Head and Neck (BRILLIANCE-HN) **A. Kartolo**

Neoadjuvant Chemotherapy and Transoral Robotic Surgery for HPV-related Oropharyngeal Cancer: Standard versus de-escalated personalized transoral robotic surgery (NECTORS-2) **N. Sadeghi**

A Randomized Phase II/III trial of Immunotherapy with Delayed and Reduced Volume Elective Radiotherapy (REVERT) in patients with High Risk HNSCC **A. McPartlin**

TITRATE: Tailored Intensity of Treatment with (chemo)Radiotherapy After Timely Evaluation **J. Tsai**

12:05 pm Break

12:15 pm Update On Approved Not Activated Trials

HN.13 - Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (**ON-TASC Study**) **I. Poon**



12:25 pm **Update on Open Trials**

HN.11- SPECT-CT Guided **E**lective **C**ontralateral Neck Treatment in Lateralized Oropharynx Cancer (**SELECT**): For Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial

**J. de Almeida
& A. Hosni**

HN.10- A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (**EVADER**) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma

S. Bratman

HN.9- Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)

A. Spreafico

HNC.2 (NRG-HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

E. Winquist

1:00 pm **Meeting Adjourned**

